118 related articles for article (PubMed ID: 24379062)
1. Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.
Li ZC; Yu HY; Wang XX; Zhang M; Wang JP
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3318-22. PubMed ID: 24379062
[TBL] [Abstract][Full Text] [Related]
2. Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan.
Wang P; Tang F; Li R; Zhang H; Chen S; Liu P; Huang H
Pharmacol Res; 2007 May; 55(5):408-17. PubMed ID: 17324585
[TBL] [Abstract][Full Text] [Related]
3. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
Albayrak S; Ordu S; Ozhan H; Yazici M; Aydin M; Alemdar R; Kaya A
Blood Press; 2009; 18(4):187-91. PubMed ID: 19521888
[TBL] [Abstract][Full Text] [Related]
4. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor.
Kasal DA; Neves MF; Oigman W; Mandarim-de-Lacerda CA
Histol Histopathol; 2008 Oct; 23(10):1241-8. PubMed ID: 18712676
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
[TBL] [Abstract][Full Text] [Related]
9. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan attenuates cardiac remodeling through DLL4/Notch1 pathway activation in pressure overload mice.
You J; Wu J; Jiang G; Guo J; Wang S; Li L; Ge J; Zou Y
J Cardiovasc Pharmacol; 2013 Feb; 61(2):142-51. PubMed ID: 23188126
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
[TBL] [Abstract][Full Text] [Related]
12. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
[TBL] [Abstract][Full Text] [Related]
13. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
[TBL] [Abstract][Full Text] [Related]
14. Regression of cardiac hypertrophy and myosin isoenzyme patterns by losartan and captopril in renovascular hypertensive rats.
Ling Q; Guo ZG; Su Z; Guo X
Zhongguo Yao Li Xue Bao; 1994 May; 15(3):206-10. PubMed ID: 7976371
[TBL] [Abstract][Full Text] [Related]
15. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
16. Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats.
Jeron A; Straub RH; Kaiser T; Riegger GA; Muders F
Immunobiology; 2002 Mar; 205(1):51-60. PubMed ID: 11999344
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.
Lee TM; Lin MS; Chou TF; Chang NC
Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1281-9. PubMed ID: 16565312
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
19. Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits.
Signolet IL; Bousquet PP; Monassier LJ
Am J Hypertens; 2008 Jan; 21(1):54-60. PubMed ID: 18091744
[TBL] [Abstract][Full Text] [Related]
20. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Nakamoto H; Imai H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S83-7. PubMed ID: 18552271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
